youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
IART:NASDAQ
Integra Lifesciences Holdings Corp
$13.41
arrow_upward
+1.51%(+0.20) 1D
Oct 19, 3:06:59 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IART...
Open
$13.13
High
$13.48
Low
$13.11
Mkt. cap
1.04B
Avg. vol.
1.09M
Volume
273.94K
52-wk high
$20.49
52-wk low
$8.70
EPS
-$0.10
Beta
1.21
Shares outstanding
77.77M
No. of employees
4K
Open
$13.13
High
$13.48
Low
$13.11
Mkt. cap
1.04B
Avg. vol.
1.09M
Volume
273.94K
52-wk high
$20.49
52-wk low
$8.70
EPS
-$0.10
Beta
1.21
Shares outstanding
77.77M
No. of employees
4K
News stories
From web sources and news partners
ACCESS Newswire
·
18 hours ago
Press Release Distribution & Media Outreach Platform for PR Agencies
https://www.dars.gov.et/
·
2 weeks ago
Integra LifeSciences (IART) Steadies Near $16.27 as Traders Eye Support at $15.46 - PSAR Stop
Profile
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds. Wikipedia
About Integra Lifesciences Holdings Corp
CEO-
Employees4.43K
Founded1989
HeadquartersPrinceton, New Jersey, United States
SectorMedical device
Websiteintegralife.com
Analyst ratings
Based on 7 analysts giving stock ratings to IART in the past 3 months
Hold
Buy
0
Hold
6
Sell
1
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for IART in the last 3 months.
Highest
Current $13.41
$19.00 (+41.69%)
Average
$16.00 (+19.31%)
Lowest
$15.00 (+11.86%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Richard Newitter Truist Financial | Hold | Maintained | $15.00 | +11.9% | 10/14/2026 |
Ravi Misra Truist Financial | Hold | Maintained | $15.00 | +11.9% | 10/14/2026 |
Joanne Wuensch Citi | Hold | Maintained | $15.00 | +11.9% | 10/05/2026 |
Ryan Zimmerman BTIG | Hold | Maintained | - | - | 10/02/2026 |
Larry Biegelsen Wells Fargo | Hold | Maintained | $15.00 | +11.9% | 10/02/2026 |
Vik Chopra BMO Capital | Hold | Maintained | $15.00 | +11.9% | 10/02/2026 |
Robbie Marcus J.P. Morgan | Sell | Maintained | $17.00 | +26.8% | 08/04/2026 |
Patrick Wood UBS | Hold | Initiated | $19.00 | +41.7% | 07/28/2026 |
Unknown Analyst BMO Capital | Hold | Initiated | $19.00 | +41.7% | 07/08/2026 |
David Toung Argus Research | Buy | Upgraded | $25.00 | +86.4% | 06/17/2026 |
Travis Steed Bank of America Securities | Sell | Maintained | - | - | 05/14/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $27.00 | +101.3% | 05/06/2026 |
Next call in 41:20:16
Wed, Oct 21, 2:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.56
Revenue / Est. (USD)
- / 412.10M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 402.06M | 434.92M | 391.92M | 418.76M |
Cost of goods sold | 172.23M | 189.79M | 163.50M | 185.09M |
Cost of revenue | 172.23M | 189.79M | 163.50M | 185.09M |
Research and development expenses | 19.28M | 19.34M | 18.70M | 22.39M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 166.94M | 167.92M | 165.16M | 167.22M |
Operating expense | 189.94M | 191.03M | 187.64M | 193.38M |
Total operating expenses | 362.17M | 380.82M | 351.13M | 378.47M |
Operating income | 39.89M | 54.10M | 40.79M | 40.29M |
Other non operating income | -5.04M | 21.30M | -2.95M | -4.62M |
EBT including unusual items | -6.82M | 4.31M | -2.41M | 4.74M |
EBT excluding unusual items | 22.15M | 34.00M | 28.15M | 27.00M |
Income tax expense | -1.42M | 6.01M | 2.21M | 262.00K |
Effective tax rate | 20.81% | 139.54% | -91.66% | 5.52% |
Other operating expenses | - | - | - | - |
Net income | -5.40M | -1.70M | -4.62M | 4.48M |
Net profit margin | -1.34% | -0.39% | -1.18% | 1.07% |
Earnings per share | 0.54 | 0.83 | 0.54 | 0.56 |
Interest and investment income | 4.98M | 4.36M | 4.11M | 4.27M |
Interest expense | -22.72M | -23.67M | -22.46M | -22.99M |
Net interest expenses | -17.74M | -19.31M | -18.36M | -18.73M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 78.41M | 92.53M | 79.22M | 78.43M |
Gain or loss from assets sale | -4.00K | - | 90.00K | 643.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1